2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 120

Patients with Rheumatoid Arthritis Have Higher Lifetime Professional and Non-Professional Exposure to Silica Dust Particles Compared to General Population
Abstract Number: 2633

Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State
Abstract Number: 339

Patients’ Attitudes and Experiences of Transitional Care in Paediatric Rheumatology: A Systematic Review of Qualitative Studies
Abstract Number: 362

Patients’ Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey
Abstract Number: 2242

Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Abstract Number: 2944

Patterns and Characteristics of Accelerated Hand Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 2241

Patterns and Outcomes on Disease Activity in Patients with Ankylosing Spondylitis (AS) Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and Influential Factors
Abstract Number: 1829

Patterns and Predictors of Progression of Sacroiliitis in Psoriatic Arthritis and Its Relationship with Human Leukocyte Antigen (HLA) Alleles. Results from the Toronto Cohort
Abstract Number: 2281

Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry
Abstract Number: 1815

Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry
Abstract Number: 224

Patterns of Methotrexate Use in African Countries with Low Versus Medium/High Human Development Index: Preliminary Results of Semi-Structured Interviews
Abstract Number: 1883

Patterns of Osteoarticular Involvement in SAPHO Syndrome: A Cluster Analysis Based on Whole Body Bone Scintigraphy in 157 Patients
Abstract Number: 1423

Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice
Abstract Number: 2320

Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years
Abstract Number: 93

Peer-Developed E-Learning Resource Can Address Rheumatology Knowledge Gaps in Junior Learners

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].